ImmunityBio (IBRX) Stock Outlook: Anktiva’s Rapid Revenue Rise Sparks Investor Interest

In July 2026, ImmunityBio’s CEO Patrick Soon-Shiong announced that Anktiva had become a commercial success, with sales surpassing expectations in its first year on the market. This milestone marked a turning point for the company, transforming it from a biotech hopeful into a revenue-generating entity, yet challenges remain. Investors are now watching closely as the company prepares for a major FDA decision on January 6, 2027, amid ongoing financial pressures.

ImmunityBio (NASDAQ: IBRX) has seen its net product revenue climb to $50.7 million in the second quarter of 2026, a 92% jump from the previous year. Despite this growth, the company reported a quarterly net loss of $230.4 million and continues to rely heavily on outside funding to sustain operations.

The next few months will reveal whether Anktiva’s sales momentum can be maintained. The FDA’s decision on expanding Anktiva’s label to include BCG-naive bladder cancer patients is critical. The mid-term outlook hinges on clinical data supporting broader use, while the long-term vision involves building a multi-indication franchise without diluting shareholder value through excessive financing.

Key Takeaways

• Anktiva plus BCG gained FDA approval in April 2024 for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
• ImmunityBio’s 2025 net product revenue soared to $113.0 million (roughly 700% above 2024) followed by $94.8 million in the first half of 2026.
• The FDA is reviewing a label expansion for papillary-only disease, with a PDUFA date set for January 6, 2027.
• Positive results from QUILT-2.005 could position Anktiva for first-line bladder cancer treatment, but final data and regulatory approval are still pending.
• The main risks include product concentration, cash burn, shareholder dilution, competition, legal issues, and the possibility that ongoing clinical programs may not succeed.
• This article provides analysis and catalyst mapping. It is not financial advice or a recommendation to buy or sell IBRX.

What ImmunityBio Does: Anktiva Is the Commercial Engine

ImmunityBio’s core asset is Anktiva, also called N-803 or nogapendekin alfa inbakicept-pmln. It’s an interleukin-15 receptor agonist designed to activate natural killer cells and T cells. Currently, the main commercial product involves direct bladder injections combined with Bacillus Calmette-Guerin, or BCG.

The FDA approved Anktiva plus BCG in April 2024 for adults with BCG-unresponsive non-muscle-invasive bladder cancer, or NMIBC, involving carcinoma in situ, with or without papillary tumors. This approval was based on data from QUILT-3.032, a multicenter, single-arm study. The approval allows commercial use, but many other potential indications remain investigational.

The FDA’s efficacy evaluation included 77 evaluable patients, supporting the current label but not yet proving effectiveness in papillary-only disease, BCG-naive patients, glioblastoma, or lung cancer. Each of these areas involves different trial designs and standards.

Expanding Anktiva’s commercial reach depends on broadening the approved bladder cancer indications into new patient groups and settings.

The Numbers: Revenue Growth Versus Cash and Financing Risk

Sales of Anktiva are rising sharply. ImmunityBio reported $113.0 million in net product revenue for 2025, an extraordinary 700% increase over 2024. In the first half of 2026, revenue reached $94.8 million, up 121% from the same period in 2025, with sequential growth each quarter.

However, the company’s expenses tell a different story. The second-quarter 2026 results show a net loss of $230.4 million, with research and development costs of $60.8 million and sales, general, and administrative expenses of $51.8 million. Operating cash flow was negative $141.9 million in the first half.

The company’s balance sheet reveals ongoing financial strain. As of June 30, 2026, ImmunityBio reported liabilities totaling $1.67 billion and a stockholders’ deficit of $1.05 billion. The company’s cash position was $357.4 million, but its liabilities (including a related-party convertible note valued at $774.4 million) pose a significant challenge.

ImmunityBio’s June 2026 Form 10-Q expresses doubts about its ability to continue as a going concern without additional capital. This warning underscores the importance of financing terms in determining the stock’s future value.

While revenue growth supports the stock’s potential, the actual ownership stake of shareholders depends heavily on how the company funds its operations. Dilutive financing could limit upside for existing investors.

Short-Term Outlook: The Next 12 Months

The immediate focus for ImmunityBio is on upcoming catalysts. The most significant is the FDA’s decision on whether to expand Anktiva’s label to include BCG-unresponsive NMIBC with papillary tumors. The agency accepted the supplemental biologics license application (sBLA) in May 2026, with a PDUFA date set for January 6, 2027.

This application is supported by data from QUILT-3.032 Cohort B, which enrolled 80 patients with high-grade papillary-only disease. Approval would significantly enlarge the market and potentially improve reimbursement prospects. But the FDA previously issued a refusal-to-file letter in May 2025, and its current review hinges on whether evidence from CIS disease can be extrapolated to papillary-only cases.

Another key program is QUILT-2.005, a randomized trial comparing Anktiva plus BCG against BCG alone in BCG-naive NMIBC patients. Interim results showed an 85% complete response rate at six months for the combination, versus 57% for BCG alone. At nine months, the rates were 84% and 52%, respectively, with a p-value of 0.0455.

Enrolled during 2026, the trial’s final analysis is expected by year-end. The company aims to submit a supplemental BLA later this year. However, these interim results are subject to change, and the ultimate clinical and regulatory success depends on confirmatory data showing durability and safety.

Quarterly sales figures will remain a key market signal. Continued sequential growth would suggest increasing adoption among urologists. Slower growth or flat sales could indicate market saturation, reimbursement hurdles, or competition. At the same time, rising expenses could offset revenue gains and heighten financing risks.

Mid-Term Outlook: One to Three Years

Beyond 2026, the potential for broader use of Anktiva depends on successful regulatory and clinical progress. A positive FDA decision on BCG-naive bladder cancer could shift the product into earlier treatment lines, expanding its market significantly.

The randomized trial design of QUILT-2.005 offers stronger evidence than the initial approval’s single-arm study. Still, the final analysis must confirm that the observed benefits hold true. Risks include regulatory setbacks, safety concerns, or limited clinical benefit that fails to change standard practice.

International expansion provides another growth avenue. Anktiva received European approval for the NMIBC indication in February 2026 and became available in Saudi Arabia in April 2026 through a partnership with Biopharma and Cigalah Healthcare. The UAE followed with approvals for NMIBC and metastatic NSCLC, raising the company’s global footprint to 34 countries.

However, international sales depend on securing reimbursement, establishing supply chains, and educating healthcare providers. Mere approvals do not guarantee commercial success.

The mid-term outlook hinges on successful randomized trials and effective commercialization across multiple regions. Outside bladder cancer, the most advanced program is for non-small-cell lung cancer. The Phase 3 trial, QUILT-2.023, faced enrollment challenges after standard treatments evolved, but early results from other studies show promise.

In a Phase 2b study, QUILT-3.055, ImmunityBio found that patients with higher lymphocyte counts had longer median overall survival, up to 21.1 months. While encouraging, these are correlational findings, not definitive proof of causality. A Phase 3 trial, ResQ201A, is testing Anktiva plus checkpoint inhibitors against chemotherapy in second-line NSCLC, which will be more definitive.

Long-Term Outlook: Three Years and Beyond

Achieving long-term success requires Anktiva to become a multi-indication asset. Expanding into papillary-only and BCG-naive bladder cancer, plus demonstrating efficacy in NSCLC or glioblastoma, could diversify revenue streams.

Glioblastoma presents high risk but also high potential. The ongoing QUILT-3.078 trial combines Anktiva with CAR-NK cells, bevacizumab, and Tumor Treating Fields. As of January 2026, 23 patients had been enrolled, with median follow-up of six months. Results are too early to draw firm conclusions, and the study’s small size limits statistical power.

Long-term profitability depends on sales growth outpacing expenses and financing obligations. Without increasing revenue faster than cash burn, shareholder value could remain constrained by debt and dilution.

The downside scenario involves continued reliance on capital markets, which could dilute existing shareholders through new equity or convertible debt. Revenue-interest financing, while providing short-term liquidity, might also divert future earnings.

Independent Evidence Versus Company Claims

The strongest evidence supporting Anktiva’s value comes from the FDA approval, the official prescribing info, and peer-reviewed publications from QUILT-3.032. These sources establish the current label and measurable response durations.

The label expansion for papillary-only disease relies on additional peer-reviewed data, but the FDA has yet to approve it. The BCG-naive program’s interim results are promising but require final confirmation. Claims for NSCLC and glioblastoma are based largely on company announcements and early-stage data, which are less definitive.

Regulatory and legal risks also matter. The FDA issued a warning letter to ImmunityBio in March 2026, citing misleading claims and omitted risk information. When the warning became public, IBRX shares fell 26%, illustrating market sensitivity to regulatory issues.

Legal challenges and shareholder lawsuits add further uncertainty. While allegations of misconduct are not proven, they can lead to costly litigation and management distraction, impacting stock performance.

Competition and Commercial Execution Risk

ImmunityBio faces competition from established and emerging therapies. Pembrolizumab is an approved immunotherapy for NMIBC, and Cretostimogene grenadenorepvec is in development for BCG-unresponsive disease. The Phase 3 BOND-003 study of Cretostimogene reported a 75.5% complete response rate, but cross-trial comparisons are limited by differing designs and endpoints.

Market success depends on factors beyond efficacy, such as durability, safety, ease of administration, BCG supply, reimbursement, and clinical evidence. A therapy with simpler administration or more robust data could limit Anktiva’s market share, even if it remains effective.

IBRX Catalysts and Risks by Time Horizon

Bottom Line for IBRX Stock Outlook

ImmunityBio has reached a pivotal milestone: Anktiva is now an approved product with growing sales, not just a pre-commercial hope. The 2025 revenue total and the first-half 2026 ramp demonstrate real market demand. The upcoming FDA decision and the QUILT-2.005 trial results could significantly expand its bladder cancer franchise.

However, risks remain substantial. The company depends heavily on a single product, continues to burn cash, and faces complex liabilities and regulatory scrutiny. Its broader oncology pipeline requires more definitive evidence. Competition, legal issues, supply chain concerns, and international hurdles add to the uncertainty.

The short-term outlook hinges on quarterly sales figures and the papillary disease decision. The mid-term depends on success in first-line bladder cancer and confirming results in NSCLC. Long-term, ImmunityBio aims for multiple indications, international expansion, and sustainable profitability, yet all face significant hurdles.

Note: This is not financial advice. IBRX remains a volatile biotech stock vulnerable to binary clinical and regulatory events. Investors should carefully review SEC filings, FDA documents, trial publications, financing conditions, and personal risk appetite before making any investment decisions.

Sources and References

Sources cited while researching and writing this article:

• approved Anktiva plus BCG in April 2024
• 2025 results announcement
• ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
• ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA …
• ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment …
• ImmunityBio Reports Median Overall Survival Not Yet Reached and …